Stocksigma LogoStocksigma Logo

Wanbury Clarifies Zero Impact on FY27 Guidance and Operations Following Investor Queries

Wanbury confirmed its business and sales remain unaffected, with US market exposure via its Tanuku facility representing approximately 6% of consolidated

Wanbury Clarifies Zero Impact on FY27 Guidance and Operations Following Investor Queries

Wanbury Ltd 路 Press Release 路 16 Nov 2026, 8:23 pm

Wanbury Clarifies Zero Impact on FY27 Guidance and Operations Following Investor Queries Wanbury confirmed its business and sales remain unaffected, with US market exposure via its Tanuku facility representing approximately 6% of consolidated YTD revenue. New ANDAs and regulatory filings will be transitioned to the Patalganga API manufacturing facility, which is US FDA-approved with zero observations from its last inspection and operating normally. Based on current assessments, the company reiterated that there is no impact on operations or its financial guidance for FY'27.

Original exchange filing (PDF)

More announcements from Wanbury Ltd

All Wanbury Ltd announcements